SWOG clinical trial number
CTSU/A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Open
Phase
Abbreviated Title
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Status Notes
Effective study closure 3/15/25
Activated
08/18/2014
Closed
03/15/2025
Participants
CTSU

Research committees

Lung Cancer

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients in The U.S. ALCHEMIST Study (Alliance)

K Kehl;D Zahrieh;P Yang;S Hillman;A Tan;J Sands;G Oxnard;E Gillespie;D Wigle;S Malik;T Stinchcombe;S Ramalingam;K Kelly;S Mandrekar;R Osarogiagbon;D Kozono WCLC World Conference on Lung Cancer (September 8-14, 2021, virtual), mini-oral, #MA15.05

2018

Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (A151216)

J Oxnard;S Mandrekar;S Hillman;A Tan;R Govindan;S Malik;C Watt;D Gerber;J Chaft;S Dahlberg;D Gandara;K Kelly;S Ramalingam;T Stinchcombe IASCL (WCLC) (September 23-26, 2018, Toronto, CAN), abst.#P1.16-47, IASLC Book of Abstracts p. 421

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase